BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28816592)

  • 1. Two-faced Fcab prevents polymerization with VEGF and reveals thermodynamics and the 2.15 Å crystal structure of the complex.
    Lobner E; Humm AS; Mlynek G; Kubinger K; Kitzmüller M; Traxlmayr MW; Djinović-Carugo K; Obinger C
    MAbs; 2017 Oct; 9(7):1088-1104. PubMed ID: 28816592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments.
    Wozniak-Knopp G; Stadlmayr G; Perthold JW; Stadlbauer K; Woisetschläger M; Sun H; Rüker F
    Protein Eng Des Sel; 2017 Sep; 30(9):657-671. PubMed ID: 28981753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fcab-HER2 Interaction: a Ménage à Trois. Lessons from X-Ray and Solution Studies.
    Lobner E; Humm AS; Göritzer K; Mlynek G; Puchinger MG; Hasenhindl C; Rüker F; Traxlmayr MW; Djinović-Carugo K; Obinger C
    Structure; 2017 Jun; 25(6):878-889.e5. PubMed ID: 28528777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered IgG1-Fc--one fragment to bind them all.
    Lobner E; Traxlmayr MW; Obinger C; Hasenhindl C
    Immunol Rev; 2016 Mar; 270(1):113-31. PubMed ID: 26864108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creating stable stem regions for loop elongation in Fcabs - insights from combining yeast surface display, in silico loop reconstruction and molecular dynamics simulations.
    Hasenhindl C; Lai B; Delgado J; Traxlmayr MW; Stadlmayr G; Rüker F; Serrano L; Oostenbrink C; Obinger C
    Biochim Biophys Acta; 2014 Sep; 1844(9):1530-40. PubMed ID: 24792385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution.
    Traxlmayr MW; Lobner E; Hasenhindl C; Stadlmayr G; Oostenbrink C; Rüker F; Obinger C
    Biotechnol J; 2014 Aug; 9(8):1013-22. PubMed ID: 24964247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display.
    Traxlmayr MW; Lobner E; Antes B; Kainer M; Wiederkum S; Hasenhindl C; Stadlmayr G; Rüker F; Woisetschläger M; Moulder K; Obinger C
    Protein Eng Des Sel; 2013 Apr; 26(4):255-65. PubMed ID: 23267121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for Targeted Drug Delivery.
    Jäger S; Wagner TR; Rasche N; Kolmar H; Hecht S; Schröter C
    Bioconjug Chem; 2021 Aug; 32(8):1699-1710. PubMed ID: 34185508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dynamics simulation of the crystallizable fragment of IgG1-insights for the design of Fcabs.
    Lai B; Hasenhindl C; Obinger C; Oostenbrink C
    Int J Mol Sci; 2014 Jan; 15(1):438-55. PubMed ID: 24451126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab).
    Kainer M; Antes B; Wiederkum S; Wozniak-Knopp G; Bauer A; Rüker F; Woisetschläger M
    Arch Biochem Biophys; 2012 Oct; 526(2):154-8. PubMed ID: 22634259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability assessment on a library scale: a rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc.
    Hasenhindl C; Traxlmayr MW; Wozniak-Knopp G; Jones PC; Stadlmayr G; Rüker F; Obinger C
    Protein Eng Des Sel; 2013 Oct; 26(10):675-82. PubMed ID: 24006374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties.
    Wozniak-Knopp G; Bartl S; Bauer A; Mostageer M; Woisetschläger M; Antes B; Ettl K; Kainer M; Weberhofer G; Wiederkum S; Himmler G; Mudde GC; Rüker F
    Protein Eng Des Sel; 2010 Apr; 23(4):289-97. PubMed ID: 20150180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.
    Woisetschläger M; Antes B; Borrowdale R; Wiederkum S; Kainer M; Steinkellner H; Wozniak-Knopp G; Moulder K; Rüker F; Mudde GC
    Biotechnol J; 2014 Jun; 9(6):844-51. PubMed ID: 24806546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yeast Surface Display and Cell Sorting of Antigen-Binding Fc Fragments.
    Sádio F; Stadlmayr G; Stadlbauer K; Rüker F; Wozniak-Knopp G
    Methods Mol Biol; 2019; 1923():287-308. PubMed ID: 30737746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
    Kuglstatter A; Stihle M; Neumann C; Müller C; Schaefer W; Klein C; Benz J;
    Protein Eng Des Sel; 2017 Sep; 30(9):649-656. PubMed ID: 28985438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of High-Affinity Heterodimeric Antigen-Binding Fc Fragments from a Large Yeast Display Library.
    Benedetti F; Stadlmayr G; Stadlbauer K; Rüker F; Wozniak-Knopp G
    Methods Mol Biol; 2023; 2681():131-159. PubMed ID: 37405647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics.
    Everett KL; Kraman M; Wollerton FPG; Zimarino C; Kmiecik K; Gaspar M; Pechouckova S; Allen NL; Doody JF; Tuna M
    Methods; 2019 Feb; 154():60-69. PubMed ID: 30208333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Design of Antiangiogenic Peptibody by Fusing Human IgG1 Fc Fragment and HRH Peptide: Structural Modeling, Energetic Analysis, and Dynamics Simulation of Its Binding Potency to VEGF Receptor.
    Ning L; Li Z; Bai Z; Hou S; He B; Huang J; Zhou P
    Int J Biol Sci; 2018; 14(8):930-937. PubMed ID: 29989101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
    Teplyakov A; Zhao Y; Malia TJ; Obmolova G; Gilliland GL
    Mol Immunol; 2013 Nov; 56(1-2):131-9. PubMed ID: 23628091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
    Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
    Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.